These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19218323)

  • 1. Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation.
    Gekas J; Gagné G; Bujold E; Douillard D; Forest JC; Reinharz D; Rousseau F
    BMJ; 2009 Feb; 338():b138. PubMed ID: 19218323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies.
    Gilbert RE; Augood C; Gupta R; Ades AE; Logan S; Sculpher M; van Der Meulen JH
    BMJ; 2001 Aug; 323(7310):423-5. PubMed ID: 11520837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing outcomes and costs between contingent and combined first-trimester screening strategies for Down's syndrome.
    Martín I; Gibert MJ; Aulesa C; Alsina M; Casals E; Bauça JM
    Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():13-8. PubMed ID: 25827079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.
    Chitty LS; Wright D; Hill M; Verhoef TI; Daley R; Lewis C; Mason S; McKay F; Jenkins L; Howarth A; Cameron L; McEwan A; Fisher J; Kroese M; Morris S
    BMJ; 2016 Jul; 354():i3426. PubMed ID: 27378786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential and contingent prenatal screening for Down syndrome.
    Wald NJ; Rudnicka AR; Bestwick JP
    Prenat Diagn; 2006 Sep; 26(9):769-77. PubMed ID: 16821246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine tests for Down's syndrome screening.
    Alldred SK; Guo B; Takwoingi Y; Pennant M; Wisniewski S; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011984. PubMed ID: 26662198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester serum tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011975. PubMed ID: 26617074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of the integrated test in the Down's syndrome screening algorithm.
    Springer D; Loucky J; Tesner P; Cutka D; Stejskal D; Gregor V; Zima T
    J Med Screen; 2018 Sep; 25(3):114-118. PubMed ID: 29575979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using decision analysis to compare policies for antenatal screening for Down's syndrome.
    Fletcher J; Hicks NR; Kay JD; Boyd PA
    BMJ; 1995 Aug; 311(7001):351-6. PubMed ID: 7640539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service.
    Morris S; Karlsen S; Chung N; Hill M; Chitty LS
    PLoS One; 2014; 9(4):e93559. PubMed ID: 24714162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of triple test in second-trimester maternal serum screening for Down's syndrome: an experience from Taiwan with decreasing birth rate but increasing population of old pregnant women.
    Hwa HL; Yen MF; Lin CL; Ko TM; Hsieh FJ; Chen TH
    J Eval Clin Pract; 2008 Apr; 14(2):191-7. PubMed ID: 18284525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
    Wald NJ; Watt HC; Hackshaw AK
    N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A.
    Spencer K
    BJOG; 2001 Oct; 108(10):1043-6. PubMed ID: 11702835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.